Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII

Adam J Salmon; Michael L Williams; Quoc Kien Wu; Julia Morizzi; Daniel John Gregg; Susan Ann Charman; D Vullo; Claudiu Trandafir Supuran; Sally-Ann Poulsen

doi:10.1021/jm300427m

Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII

Adam J Salmon, Michael L Williams, Quoc Kien Wu, Julia Morizzi, Daniel John Gregg, Susan Ann Charman, D Vullo, Claudiu Trandafir Supuran, Sally-Ann Poulsen

Centre for Drug Candidate Optimisation

Research output: Contribution to journal › Article › Research › peer-review

60 Citations (Scopus)

Abstract

In this article, we report the design, synthesis, biological activity, and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX is a new approach with potential to deliver organometallic, drug-like compounds as future therapies.

Original language	English
Pages (from-to)	5506 - 5517
Number of pages	12
Journal	Journal of Medicinal Chemistry
Volume	55
Issue number	11
DOIs	https://doi.org/10.1021/jm300427m
Publication status	Published - 2012

Cite this

Salmon, A. J., Williams, M. L., Wu, Q. K., Morizzi, J., Gregg, D. J., Charman, S. A., ... Poulsen, S-A. (2012). Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. Journal of Medicinal Chemistry, 55(11), 5506 - 5517. https://doi.org/10.1021/jm300427m

@article{cd5109da0cfc460c8ee31e2ffda6cfdc,

title = "Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII",

abstract = "In this article, we report the design, synthesis, biological activity, and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX is a new approach with potential to deliver organometallic, drug-like compounds as future therapies.",

author = "Salmon, {Adam J} and Williams, {Michael L} and Wu, {Quoc Kien} and Julia Morizzi and Gregg, {Daniel John} and Charman, {Susan Ann} and D Vullo and Supuran, {Claudiu Trandafir} and Sally-Ann Poulsen",

year = "2012",

doi = "10.1021/jm300427m",

language = "English",

volume = "55",

pages = "5506 -- 5517",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "AMER CHEMICAL SOC",

number = "11",

}

Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. / Salmon, Adam J; Williams, Michael L; Wu, Quoc Kien; Morizzi, Julia; Gregg, Daniel John; Charman, Susan Ann; Vullo, D; Supuran, Claudiu Trandafir; Poulsen, Sally-Ann.

In: Journal of Medicinal Chemistry, Vol. 55, No. 11, 2012, p. 5506 - 5517.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII

AU - Salmon, Adam J

AU - Williams, Michael L

AU - Wu, Quoc Kien

AU - Morizzi, Julia

AU - Gregg, Daniel John

AU - Charman, Susan Ann

AU - Vullo, D

AU - Supuran, Claudiu Trandafir

AU - Poulsen, Sally-Ann

PY - 2012

Y1 - 2012

N2 - In this article, we report the design, synthesis, biological activity, and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX is a new approach with potential to deliver organometallic, drug-like compounds as future therapies.

AB - In this article, we report the design, synthesis, biological activity, and selected ADME properties for a library of novel metallocene-based CA inhibitors. The development of metallocene-based compounds that can selectively kill tumor cells by inhibiting the validated oncology target CA IX is a new approach with potential to deliver organometallic, drug-like compounds as future therapies.

UR - http://pubs.acs.org/doi/abs/10.1021/jm300427m

U2 - 10.1021/jm300427m

DO - 10.1021/jm300427m

M3 - Article

VL - 55

SP - 5506

EP - 5517

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -

Access to Document

10.1021/jm300427m

RM sElocation